A study in healthy volunteers to assess safety and blood levels of AZD9742 after multiple doses over 14 days
Study identifier:D2690C00002
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
A Phase I, Single Center, Double-blind Randomized, Placebo-controlled, Parallel-group Study to Assess the Safety, Tolerability and Pharmacokinetics of Intravenous AZD9742 after Administration of Multiple Ascending Doses for 14 days in Healthy Male and Female Subjects
Medical condition
Healthy
Phase
Phase 1
Healthy volunteers
Yes
Study drug
AZD9742, Placebo
Sex
All
Actual Enrollment
36
Study type
Interventional
Age
23 Years - 45 Years
Date
Study Start Date: 01 Feb 2010
Primary Completion Date: 01 Aug 2010
Study Completion Date: 01 Aug 2010
Study design
Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment
Verification:
Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|---|
| Experimental: 1 | Drug: AZD9742 IV infusion, 15 days |
| Placebo Comparator: 2 | Drug: Placebo IV infusion, 15 days |
Contacts
Investigators
Principal Investigator
Andrew Shaw
AstraZeneca
